nach oben

Erschienen in:

01.05.2010 | Original Article—Liver, Pancreas, and Biliary Tract

Clinical usefulness of 18F-FDG PET-CT for patients with gallbladder cancer and cholangiocarcinoma

verfasst von: Seung Won Lee, Hong Joo Kim, Jung Ho Park, Dong Il Park, Yong Kyun Cho, Chong Il Sohn, Woo Kyu Jeon, Byung Ik Kim

Erschienen in: Journal of Gastroenterology | Ausgabe 5/2010

Einloggen, um Zugang zu erhalten

Abstract

Background

Reports concerning the clinical usefulness of ¹⁸F 2-fluoro-2-deoxy-d-glucose integrated positron emission and computed tomography (¹⁸F-FDG PET-CT) for patients with gallbladder cancer and cholangiocarcinoma are relatively scarce. The purpose of this study was to assess the diagnostic value of PET-CT in relation to a conventional imaging modality, multidetector row CT (MDCT), for patients with gallbladder cancer and cholangiocarcinoma.

Methods

Ninety-nine patients with suspected gallbladder cancer and cholangiocarcinoma who underwent both PET-CT and MDCT for initial staging were included in our study. The results of these two imaging modalities for evaluating primary tumors, regional lymph nodes and distant metastases were compared with the final diagnoses based on pathological or clinical findings.

Results

A maximum standardized uptake value (SUV_max) of 3.65 was found to be the best cutoff value for detecting a malignant tumor. The overall values for the sensitivities, specificities, positive predictive values (PPVs), negative predictive values (NPVs) and the accuracies of PET-CT and MDCT for the detection of a primary tumor were 90.2, 70.6, 93.7, 60.0, 86.9% and 84.2, 70.6, 93.2, 48.0, 81.8%, respectively. PET-CT demonstrated no significant advantage over MDCT for the diagnosis of a primary tumor. PET-CT showed a significantly higher PPV (94.1 vs. 77.5%, P = 0.04) than that found for MDCT in the diagnosis of regional lymph node metastasis. Additionally, PET-CT showed a significantly higher sensitivity (94.7 vs. 63.2%, P = 0.02) than that found for MDCT in the diagnosis of distant metastasis.

Conclusions

PET-CT is valuable for detecting regional lymph node involvement and unsuspected distant metastases that are not diagnosed by MDCT.

Farley DR, Weaver AL, Nagorney DM. “Natural history” of unresected cholangiocarcinoma: patient outcome after noncurative intervention. Mayo Clin Proc. 1995;70:425–9.CrossRefPubMed

Ruckert JC, Ruckert RI, Gellert K, Hecker K, Muller JM. Surgery for carcinoma of the gallbladder. Hepatogastroenterology. 1996;43:527–33.PubMed

Miyazaki M, Ito H, Nakagawa K, Ambiru S, Shimizu H, Okuno A, et al. Does aggressive surgical resection improve the outcome in advanced gallbladder carcinoma? Hepatogastroenterology. 1999;46:2128–32.PubMed

Chijiiwa K, Tanaka M. Carcinoma of the gallbladder: an appraisal of surgical resection. Surgery. 1994;115:751–6.PubMed

Fong Y, Jarnagin W, Blumgart LH. Gallbladder cancer: comparison of patients presenting initially for definitive operation with those presenting after prior noncurative intervention. Ann Surg. 2000;232:557–69.CrossRefPubMed

Jarnagin WR, Fong Y, DeMatteo RP, Gonen M, Burke EC, Bodniewicz BJ, et al. Staging, resectability, and outcome in 225 patients with hilar cholangiocarcinoma. Ann Surg. 2001;234:507–17; discussion 517–9.

Morimoto Y, Tanaka Y, Ito T, Nakahara M, Nakaba H, Nishida T, et al. Long-term survival and prognostic factors in the surgical treatment for intrahepatic cholangiocarcinoma. J Hepatobiliary Pancreat Surg. 2003;10:432–40.CrossRefPubMed

de Groen PC, Gores GJ, LaRusso NF, Gunderson LL, Nagorney DM. Biliary tract cancers. N Engl J Med. 1999;341:1368–78.CrossRefPubMed

Park MS, Kim TK, Kim KW, Park SW, Lee JK, Kim JS, et al. Differentiation of extrahepatic bile duct cholangiocarcinoma from benign stricture: findings at MRCP versus ERCP. Radiology. 2004;233:234–40.

10.

Cha JM, Kim MH, Jang SJ. Early bile duct cancer. World J Gastroenterol. 2007;13:3409–16.PubMed

11.

Hany TF, Steinert HC, Goerres GW, Buck A, von Schulthess GK. PET diagnostic accuracy: improvement with in-line PET-CT system: initial results. Radiology. 2002;225:575–81.CrossRefPubMed

12.

Lardinois D, Weder W, Hany TF, Kamel EM, Korom S, Seifert B, et al. Staging of non-small-cell lung cancer with integrated positron-emission tomography and computed tomography. N Engl J Med. 2003;348:2500–7.CrossRefPubMed

13.

Selzner M, Hany TF, Wildbrett P, McCormack L, Kadry Z, Clavien PA. Does the novel PET/CT imaging modality impact on the treatment of patients with metastatic colorectal cancer of the liver? Ann Surg. 2004;240:1027–34. discussion 1035–6.CrossRefPubMed

14.

Heinrich S, Goerres GW, Schafer M, Sagmeister M, Bauerfeind P, Pestalozzi BC, et al. Positron emission tomography/computedtomography influences on the management of resectable pancreatic cancer and its cost-effectiveness. Ann Surg. 2005;242:235–43.CrossRefPubMed

15.

Kim JY, Kim MH, Lee TY, Hwang CY, Kim JS, Yun SC, et al. Clinical role of 18F-FDG PET-CT in suspected and potentially operable cholangiocarcinoma: a prospective study compared with conventional imaging. Am J Gastroenterol. 2008;103:1145–51.

16.

Antoch G, Saoudi N, Kuehl H, Dahmen G, Mueller SP, Beyer T, et al. Accuracy of whole-body dual-modality fluorine-18-2-fluoro-2-deoxy-d-glucose positron emission tomography and computed tomography (FDG-PET/CT) for tumor staging in solid tumors: comparison with CT and PET. J Clin Oncol. 2004;22:4357–68.CrossRefPubMed

17.

Lim JH. Cholangiocarcinoma: morphologic classification according to growth pattern and imaging findings. Am J Roentgenol. 2003;181:819–27.

18.

Greene FL, Page DL, Flemming ID, Fritz A, Balch CM, Haller DG, et al. AJCC cancer staging manual, 6th ed. New York: Springer; 2002.

19.

Petrowsky H, Wildbrett P, Husarik DB, Hany TF, Tam S, Jochum W, et al. Impact of integrated positron emission tomography on staging and management of gallbladder cancer and cholangiocarcinoma. J Hepatol. 2006;45:43–50.CrossRefPubMed

20.

Jadvar H, Henderson RW, Conti PD. [F-18] Fluorodeoxyglucose positron emission tomography and positron emission tomography: computed tomography in recurrent and metastatic cholangiocarcinoma. J Comput Assist Tomogr. 2007;31:223–8.CrossRefPubMed

21.

Kato T, Tsukamoto E, Kuge Y, Katoh C, Nambu T, Nobuta A, et al. Clinical role of 18F-FDG PET for initial staging of patients with extrahepatic bile duct cancer. Eur J Nucl Med. 2002;29:1047–54.CrossRef

Titel: Clinical usefulness of 18F-FDG PET-CT for patients with gallbladder cancer and cholangiocarcinoma
verfasst von: Seung Won Lee
Hong Joo Kim
Jung Ho Park
Dong Il Park
Yong Kyun Cho
Chong Il Sohn
Woo Kyu Jeon
Byung Ik Kim
Publikationsdatum: 01.05.2010
Verlag: Springer Japan
Erschienen in: Journal of Gastroenterology / Ausgabe 5/2010
Print ISSN: 0944-1174
Elektronische ISSN: 1435-5922
DOI: https://doi.org/10.1007/s00535-009-0188-6

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

19.04.2024 | Vorhofflimmern | Nachrichten

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Clinical usefulness of 18F-FDG PET-CT for patients with gallbladder cancer and cholangiocarcinoma

Abstract

Background

Methods

Results

Conclusions

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Parodontalbehandlung verbessert Prognose bei Katheterablation

Antihypertensiva schützen auch alte Menschen noch vor Demenz

Stereotaktische Radiatio schlägt konventionelle Bestrahlung

Denken Sie bei starker Blutung auch an die Hemmkörper-Hämophilie

Update Innere Medizin

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Abstract

Background

Methods

Results

Conclusions

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 5/2010

A guideline to fill the gap between endoscopists and physicians who prescribe anticoagulant and/or antiplatelet agents

Therapeutic factors considered according to the preoperative splenic volume for a prolonged increase in platelet count after partial splenic embolization for liver cirrhosis

Reply: A guideline to fill the gap between endoscopists and physicians who prescribe anticoagulant and/or antiplatelet agents

Mechanism of interdigestive migrating motor complex in conscious dogs

Genetics of inflammatory bowel disease in Japan

Protein profiles of peripheral blood mononuclear cells are useful for differential diagnosis of ulcerative colitis and Crohn’s disease

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Parodontalbehandlung verbessert Prognose bei Katheterablation

Antihypertensiva schützen auch alte Menschen noch vor Demenz

Stereotaktische Radiatio schlägt konventionelle Bestrahlung

Denken Sie bei starker Blutung auch an die Hemmkörper-Hämophilie

Update Innere Medizin